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The new Center for Global Health and Infectious Disease  
at Washington University serves as a hub for numerous 
initiatives. For example, because urinary tract infections 
cause significant suffering and medical care costs world-
wide, researchers are working to better understand,  
treat and prevent their recurrence. This image shows the 
colorfully stained tissue of an infected bladder and its 
dark interior cavity, called the lumen. The bladder lining, 
light blue, is expelling E. coli bacteria, green, into the 
lumen. Proliferating cell nuclei, red, reveal the organ’s 
attempt to restore a protective barrier.
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At the genetic level, any two people are more than  
99 percent alike. But rare variants — those that occur 
with a frequency of 1 percent or less in a population 
— are thought to contribute to rare diseases as well  
as common conditions like cancer and heart disease.
y decoding the genomes of more 
than 1,000 people whose home-
lands stretch from Africa and Asia 
to Europe and the Americas, scientists have 
compiled the largest and most detailed cata-
log yet of human genetic variation.
The 1000 Genomes Project involved some 
200 scientists at Washington University School 
of Medicine and other institutions. Results 
detailing DNA variations of individuals from  
14 ethnic groups were published Oct. 31 in the 
journal Nature. Eventually, the initiative will 
involve 2,500 individuals from 26 populations. 
“With this resource, researchers have a 
road map to search for the genetic origins of 
diseases in populations around the globe,” 
says one of the study’s co-principal investiga-
tors, Elaine R. Mardis, PhD, co-director of The 
Genome Institute at Washington University. 
“We estimate that each person carries up to 
several hundred rare DNA variants that could 
potentially contribute to disease.”
During the pilot phase of the effort, the 
researchers found that most rare variants  
differed from one population to another, and 
that they developed recently in human evo-
lutionary history, after populations in Europe, 
Africa, Asia and the Americas diverged from a 
single group. The current study bears this out. 
“This information is crucial and will 
improve our interpretation of individual 
genomes,” says another of the study’s  
co-principal investigators, Richard K. Wilson, 
PhD, director of The Genome Institute and a 
pioneer in cancer genome sequencing.
All study participants submitted anony-
mous DNA samples and agreed to have their 
genetic data included in an online database. 
The researchers first sequenced the entire 
genome — all the DNA — of each individual. 
To find the rare variants, they sequenced the 
small portion of the genome that contains 
genes — about 80 times for each participant 
to ensure accuracy — and they looked closely 
for single letter changes in the DNA sequence 
called SNPs (single-nucleotide polymorphisms). 
The researchers discovered 38 million SNPs 
and numerous structural variations, both of 
which can help explain an individual’s suscepti-
bility to disease, response to drugs or reaction 
to environmental factors.
“This tremendous resource builds on the 
knowledge of the Human Genome Project,” 
says co-author George M. Weinstock, PhD, 
associate director of The Genome Institute. 
“Scientists and, ultimately, patients worldwide 
will benefit from the extensive effort to under-
stand the shared features and geographic 
diversity of the human genome.”
A global search for the underlying roots of disease
Genetic portraits
New data may explain an 
individual’s susceptibility 
to disease, response to 
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Washington University School of Medicine has received a  
$50 million grant to help speed the translation of scientific 
discoveries into improvements in human health. 
The grant, from the National Institutes of Health (NIH), 
supports the school’s Institute of Clinical and Translational 
Sciences (ICTS), one of 60 such centers in the United States.
“We’re working to advance clinical and translational 
research throughout the university,” says ICTS director 
Bradley A. Evanoff, MD, assistant dean for clinical and 
translational research. “The ICTS is not built around one 
specific disease or clinical specialty. We are charged with 
speeding the application of research findings in prevention, 
diagnosis and treatment across a wide spectrum of health 
conditions and research disciplines.”
The grant is a renewal of a Clinical and Translational 
Science Award (CTSA), funded through the new National 
Center for Advancing Translational Sciences (NCATS), 
which is a part of the NIH.
Evanoff says the ICTS 
will support Washington 
University’s strengths and,  
in doing so, help pursue  
the goals of the BioMed 21 
initiative to encourage cross-
disciplinary and translational research. Over the next five 
years, the ICTS will increasingly focus on promoting three 
areas: translating research in genetics and genomics into 
patient care, developing and evaluating new therapeutics, 
and improving ways to disseminate and implement research 
findings so they become part of regular medical practice.
Other major goals of the ICTS include providing financial 
support and training for new investigators in clinical and 
translational research, building new research support infra-
structure, encouraging collaborations among faculty across 
disciplines, and creating pathways for investigators to find 
and utilize existing research resources.
Evanoff also emphasizes that the ICTS is a regional  
consortium that includes important partnerships with  
BJC HealthCare, Barnes-Jewish Hospital, St. Louis Children’s 
Hospital, Saint Louis University, the St. Louis College of 
Pharmacy, the Goldfarb School of Nursing, and the nursing 
schools at the University of Missouri-St. Louis and Southern 
Illinois University-Edwardsville.
“Together with our regional and national partners, our 
mission is to connect research findings to their eventual 
application in improving the health of the public,” Evanoff 
says. “That’s the exciting part of translational research.”
Listen, talk, read   Andrea Martin, a teacher at CID– 
Central Institute for the Deaf, works with children who are deaf or 
hard of hearing to help them “listen, talk, read and succeed.” CID 
partners with the School of Medicine’s Program in Audiology and 
Communication Sciences (PACS) as a training site for its graduate  
education programs, which include a Doctor of Audiology (AuD), 
a Master of Science in Deaf Education (MSDE), and a Doctor of 
Philosophy (PhD), as well as the new minor in Speech and Hearing 
Sciences for undergraduates. PACS is part of a consortium of programs 
known as CID at Washington University School of Medicine, which 








Fraser heads Department of Medicine
Victoria J. Fraser, MD, has been named head of the school’s 
Department of Medicine. With more than 400 faculty 
members, the department is the largest of the School of 
Medicine’s departments. It receives more grant funding than 
any other research enterprise at the 
school and is the largest clinical  
service at Barnes-Jewish Hospital.
Fraser, the Adolphus Busch 
Professor of Medicine and co-
director of the Division of Infectious 
Diseases, had been interim head of 
the department since August 2010.
“I am honored to get the opportu-
nity to serve in the same position as 
some of the key physician-scientists 
who built the School of Medicine 
into a world leader in research and 
clinical services,” Fraser says. “I look 
forward to the challenge of maintaining the department’s 
excellence and building upon that foundation as we face 
future challenges.”
Fraser also is co-principal investigator of the Washington 
University Institute of Clinical and Translational Sciences 
and is principal investigator of the research, education,  
training and clinical development arm. She also serves as 
physician-in-chief at Barnes-Jewish Hospital.
 
The Institute of Clinical 
and Translational Sciences 
serves as a bridge between 
basic and clinical science.
Translational research moves 
findings to medical practice
























Victoria J. Fraser, MD
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Wayne M. Yokoyama, MD, and Charles F. Zorumski, MD,  
have been elected to the Institute of Medicine, a part of  
the National Academy of Sciences. The two were among  
70 members so honored based on their contributions to 
advancing public health, health care and medical science.
Yokoyama is the Sam J. Levin and Audrey Loew Levin 
Professor of Research in Arthritis and professor of medi-
cine and of pathology and immunology. In 2007, he became 
director of the Medical Scientist Training Program at 
Washington University.
Also an investigator of 
the Howard Hughes Medical 
Institute and a rheumatolo-
gist at Barnes-Jewish Hospital, 
Yokoyama is known interna-
tionally for his research on 
the immune system, especially 
into the workings of natural 
killer (NK) cells. NK cells 
monitor the “credentials” of 
cells in the body, targeting for 
elimination those that lack the 
proper identification, such as 
tumor cells and those infected 
with viruses.
Zorumski is the Samuel B. 
Guze Professor of Psychiatry 
and Neurobiology and head of 
the Department of Psychiatry. 
He also serves as psychiatrist-
in-chief at Barnes-Jewish 
Hospital and director of the 
McDonnell Center for Cellular 
and Molecular Neurobiology. 
His work focuses on neuron 
communication in the brain, 
especially in the hippocampus, 
and on understanding how 
neurotransmitters and neuro-
modulators facilitate learning and memory.
His work studying anesthetic drugs led to the recent 
formation of the Taylor Family Institute for Innovative 
Psychiatric Research. Under Zorumski’s leadership, the goal 
of the institute is to understand the roles of natural and 
synthetic neurosteroid molecules in psychiatric illnesses like 
depression and schizophrenia, and to identify neurosteroid 
targets that could lead to new therapies.
Two faculty members elected  
to NAS’ Institute of Medicine 
Medical science contributions honored
Enjoy interactive elements and added content
The Program in Physical Therapy at Washington University 
School of Medicine has received a five-year, $4.6 million  
grant to continue an interdisciplinary training program for 
occupational and physical therapists that began in 2007.
Michael J. Mueller, PhD, professor of physical therapy, is 
principal investigator of the Washington University-based 
multicenter grant, called the Comprehensive Opportunities 
for Rehabilitation Research Training (CORRT).
Supported by the Eunice Kennedy Shriver National 
Institute of Child Health and Human Development of the 
National Institutes of Health (NIH), CORRT helps new 
physical and occupational therapists acquire the necessary  
skills to become independent 
researchers. Successful applicants 
train with at least two senior  
mentors: a physical or occupational 
therapist and another researcher 
from a different discipline. Twenty 
Washington University faculty from 
diverse areas are available to serve 
as mentors along with more than 40 other researchers from 
partner sites across the country.
“We’re very excited about the program’s progress,” says 
Mueller. “So far, six of the 17 scholars have earned individual 
NIH grants. We look forward to our scholars’ continued suc-
cess with the ultimate goal of helping them launch research 
that will improve the lives of people with disabilities.”
The new funding allows the program to develop a  
communication network, headed by M. Carolyn Baum, PhD, 
director of the Program in Occupational Therapy, and add 
three new training sites: Boston University, Colorado State 
University and the University of Colorado, Denver. Current 
sites include Emory University, Johns Hopkins School of 
Medicine, University of Delaware, University of Iowa and  
the University of Pittsburgh.
Physical therapy grant funds training
With honors    
Second-year medical  
student Stephen W. 
Chi, shown here with 
Koong-Nah Chung, PhD, 
associate dean for medical 
student research, received the 
Washington University Summer 
Research Prize at the annual student 
awards luncheon held in November. Chi, under 
the guidance of  David C. Beebe, PhD, is studying the proliferation of 
corneal epithelial stem cells, which has implications in corneal repair 
and transplants. Second-year medical student Nicholas S. Yozamp, 
working with Steven L. Brody, MD, also won a summer research prize.
 
The renewed grant helps  
new physical and occupa-
tional therapists acquire the 

















Wayne M. Yokoyama, MD
Charles F. Zorumski, MD
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hildren who use inhaled steroids 
for asthma end up slightly shorter 
at their full adult height than 
children who don’t use the drugs, new results 
from a comprehensive asthma study show.
The findings were published online on 
Sept. 3, 2012, in the New England Journal 
of Medicine. The study’s senior author is 
Robert C. Strunk, MD, the Donald Strominger 
Professor of Pediatrics. 
The study involved more than 1,000  
children ages five to 12 who were treated 
for mild to moderate asthma as part of the 
Childhood Asthma Management Program 
(CAMP) clinical trial. The children received 
treatment for more than four years at eight 
centers, including Washington University 
School of Medicine. 
Study participants were divided into three 
groups: one received twice-daily budesonide, 
an inhaled corticosteroid medication; a sec-
ond group received nedocromil, an inhaled 
non-steroid medication; and a third group 
received a placebo. All children received 
Do asthma steroids measure up?
C








albuterol, a fast-acting drug for relief of acute 
asthma symptoms, and oral corticosteroids  
as needed for asthma symptoms.
The researchers followed 943 participants 
at regular intervals until they reached adult 
height (females, age 18; males, age 20). The 
mean adult height was about one-half inch, 
or 1.2 centimeters, shorter in the group that 
received budesonide than in the patients 
who received nedocromil or a placebo. The 
patients who experienced the slower growth 
were primarily between five to 11 years old 
when they began using budesonide.
The slower growth took place only in the 
first two years of the four-year study. As the 
study progressed, the children who took the 
budesonide remained one-half inch shorter 
through adulthood than those who did not.
“This was surprising because in previous 
studies, we found that the slower growth was 
temporary, not affecting adult height,” says 
Strunk, who treats children with asthma at  
St. Louis Children’s Hospital. “But none of 
those studies followed patients from the  
time they entered the study until they had 
reached adult height.”
Strunk, the CAMP study chair, says 
researchers considered other factors that also 
might have contributed to the slower growth 
rate, but found these to have no impact.
“If a child is not growing as they should, 
we may reduce their steroid dose,” he says. 
“But that half-inch of lowered adult height 
must be balanced against the well-estab-
lished benefit of inhaled corticosteroids in 























The best start   A study led 
by Roberta G. Pineda, PhD, research 
assistant professor of occupational 
therapy and of pediatrics, far left, has 
documented developmental differences 
between premature babies in the NICU 
and full-term babies. Pineda’s work 
with premature babies, observed by 
students from the school’s Program 
in Occupational Therapy, points 
to intervention in the NICU to 
improve preemies’ long-term 
outcomes. Terrie E. Inder, MD, 
professor of pediatrics, is 
the principal investigator  
for the study, which is  
funded by the National 
Institutes of Health (NIH).
Pediatric asthma specialists at St. Louis Children’s Hospital 
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Researchers at Washington University School of Medicine 
have received a $9 million grant to investigate blood-clotting 
disorders. From heart attacks and strokes to uncontrolled 
bleeding, clotting disorders cause more deaths each year in 
the United States than all types of cancer combined.
“Blood clots in veins and arteries remain one of the great 
killers,” says principal investigator J. Evan Sadler, MD, 
PhD, professor of medicine and chief of the Division of 
Hematology. “The goal of this grant is to shorten the time 
between a new discovery in blood clotting or bleeding disor-
ders and the application of that knowledge to help patients.”
Washington University is one of only five universities 
across the country receiving funding from the National 
Heart, Lung, and Blood Institute (NHLBI) to support a 
new Translational Research Center in Thrombotic and 
Hemostatic Disorders.
At Washington University, researchers are focusing on 
five projects that look at bleeding disorders, including some 
that are rare, and clot 
formation in both large 
and small blood vessels. 
Sadler emphasizes the 
value of studying uncom-
mon bleeding disorders.
“Many discoveries in 
this field have been made 
by the careful investiga-
tion of unique patients 
with inherited disorders 
that are quite rare,” 
Sadler says. “But the 
knowledge gained from 
studying those patients 
has provided a foothold 
into understanding 
thrombosis or bleeding 
in humans generally.”
The five initial 
projects will be led by 
Sadler, John P. Atkinson, 
MD, the Samuel Grant 
Professor of Medicine, Enrico Di Cera, MD, professor 
and chairman of biochemistry at Saint Louis University, 
George J. Broze, MD, professor of medicine, and Samuel A. 
Wickline, MD, professor of medicine.
The grant also supports several core resources, such as a 
tissue banking core, and an educational component.
New center to study bleeding 
disorders and clot formation








Neurologists at the School of Medicine have received funding 
to study the brain following repeat concussions. The project is 
one of 15 nationally selected by NFL Charities, the charitable 
foundation of the National Football League Owners.
“We are excited about investigating what happens to the 
brain’s wiring system following concussions,” says David L. 
Brody, MD, PhD, associate professor of neurology. “We’re 
honored that the NFL has given us the opportunity to 
contribute to a greater understanding of the aftereffects of 
repetitive concussive brain injuries. We hope that this will 
lead to better ways to prevent and 
treat them.”
The NFL-funded project will use a 
type of magnetic resonance imaging 
(MRI) to measure damage in the brain’s 
white matter after repetitive concussive 
brain injury. The white matter consists 
primarily of long nerve cell extensions 
called axons that serve as the brain’s 
wiring system.
Last year, Brody’s group published a paper in the New 
England Journal of Medicine describing how they used the 
same MRI method to analyze the wiring in the brains of U.S. 
military personnel who had suffered blast-related injuries.
“There are a number of differences between blast-related 
injuries and repetitive sports-related concussions,” Brody 
says. “So it will be critical to validate the MRI method in 
a model of repetitive concussion to help us understand the 
meaning of any findings we may observe.”
NFL funds brain concussion study
Strands of a protein called von Willebrand 
Factor (orange) play a key role in blood  
clotting. Secreted by cells lining the blood  
vessels, the strands capture platelets and  
initiate the formation of blood clots.
Visionary research   Andrew Yoo, PhD, Robert W. 
Gereau IV, PhD, and Michael R. Bruchas, PhD, have been awarded 
grants from the National Institutes of Health (NIH) Common Fund to 
pursue innovative ideas that have the potential to transform science 
and improve public health. The awards are part of a High Risk-High 
Reward program that provides opportunities for innovative investi-
gators in any area of health research to take risks when the potential 
impact in biomedical and behavioral science is high. To learn more 
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ung cancer patients with a history 
of smoking have 10 times more 
genetic mutations in their tumors 
than those with the disease who have never 
smoked, according to a new study from 
Washington University School of Medicine.
“None of us were surprised that the 
genomes of smokers had more mutations 
than the genomes of never-smokers with 
lung cancer,” says senior author Richard 
K. Wilson, PhD, director of the university’s 
Genome Institute. “But it was surprising to 
see 10-fold more mutations. It does rein-
force the old message — don’t smoke.”
The study appeared online Sept. 13 in 
the journal Cell.
Overall, the analysis identified about 
3,700 mutations across all 17 patients with 
non-small cell lung cancer. Twelve patients 
had a history of smoking and five did not. 
In each patient who never smoked, the 
researchers found at least one mutated 
gene that can be targeted with drugs cur-
rently on the market for other diseases or 
Big impacts on smokers’ genes
L
o n c o l o g y  a n d  g e n e t i c s
available through clinical trials. Across all 
patients, they identified 54 mutated genes 
already associated with existing drugs.
“Whether these drugs will actually work 
in patients with these DNA alterations 
still needs to be studied,” says first author 
Ramaswamy Govindan, MD, an oncologist 
at the Alvin J. Siteman Cancer Center at 
Barnes-Jewish Hospital and Washington 
University School of Medicine. “But papers 
like this open up the landscape to under-
stand what’s happening. Now we need to 
drill deeper to understand how these  
mutations cause and promote cancer, and 
how they can be targeted for therapy.”
Lung cancer is divided into two types 
— small cell and non-small cell, the latter 
accounting for about 85 percent of all cases. 
Within non-small cell lung cancer are three 
further classifications. This current analysis 
included two: sixteen patients had adeno-
carcinoma; one had large-cell carcinoma.
Govindan and Wilson also were involved 
in a larger genomic study of 178 patients 
with the third type, squamous cell carci-
noma, recently reported in Nature. That 
study was part of The Cancer Genome Atlas 
project, a national effort to describe the 
genetics of common cancers. According 
to Govindan, research is moving toward 
clinical trials that will focus on the specific 
molecular biology of a patient’s cancer.
Based on this emerging body of genetic 
research demonstrating common muta-
tions across disparate cancer types, Wilson 
speculates that the field may reach a point 
where doctors can label and treat a tumor 
based on the genes that are mutated rather 
than the affected organ. 
tl  
Compared to other lung cancer patients, smokers  
have 10 times more genetic damage in their tumors.
Posted!  Attendance was high at 
the seventh annual Research Training 
Symposium and Poster Session held at 
the School of Medicine’s Farrell Learning 
and Teaching Center in October. The 
event, which showcases basic, clinical 
and translational projects by junior 
faculty, fellows, residents and training 
program students, also featured keynote 
speaker Curtis L. Lowery Jr., MD, director 
of Maternal Fetal Medicine and chair and 
director of the Department of Obstetrics 
and Gynecology at the University of 
Arkansas for Medical Sciences. The 
symposium is sponsored by the Clinical 
Research Training Center of the Institute 
of Clinical and Translational Sciences and 
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 CENTER 
 PIECE
Outdoor gathering place 
has a growing reputation
P H O T O  E S S A Y  B Y  
R O B E R T  B O S T O N
Washington University’s Medical
The Ellen S. Clark Hope Plaza  
was designed by artist Maya Lin  
with landscape architect Michael 
Van Valkenburgh Associates, Inc.
Outlook  9
A plan for all seasons —  
that was the intent behind the Ellen S.  
Clark Hope Plaza and its surrounding  
landscaping. This expansive and  
welcoming green space in the middle of  
Washington University Medical Center  
has been a point of convergence for the  
School of Medicine community and its  
visitors for the past two years.  
       Native greenery — including canopy trees consisting of  
swamp white oak, Kentucky coffee tree and willow, with 
understory plantings of large drifts of riparian sedges, grasses 
and flowering perennials — are alive and in tune with nature,  
as evidenced by birds nesting in the area, goldfinches eating the 
plentiful coneflower seed heads, and butterflies sipping nectar 
from the flowers. Flora that grew throughout the Midwest 
centuries ago have returned to reinvigorate the campus.
125193_Plaza_8-13_CS5.indd   9 12/10/12   3:43 PM
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Relatively common in and of 
themselves, what makes the plants 
surrounding the fountain unique is 
their combination. As a group, they 
represent a natural river bottom 
plant community. The diversity of 
this landscape can be seen nowhere 
else in the region at this scale. 
FROM LEF T:  ostrich fern, purple coneflower,  
yellow wingstem, aromatic astor, garden phlox  
and creek oats 
BACKGROUND: water lilies
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As part of a larger picture that includes brush 
strokes from local history, wildlife, ecology, education 
and evolving thoughts about the planned landscape, 
these plants belong here — as do the people who come 
to enjoy the respite provided by this verdant oasis.
Winter 201212  Washington University School of Medicine
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B Y  J I M  D R Y D E N
C R E AT E D  I N  T H E  L AT E  1 9 T H  C E N T U R Y,  H E R O I N  
— an opiate analgesic first formulated to treat severe pain —  
has had a long and not-so-pristine existence. As other drugs go 
in and out of fashion, heroin remains a staple of the illegal drug 
trade, a favorite of users for its easy availability and the euphoric 
“high” it produces.
The continuing “popularity” of heroin has never been 
lost on Theodore J. Cicero, PhD, who has been studying 
the drug and its abuse for the past four decades.
But even he admits surprise at the latest wrinkle in  
the heroin game: A reformulation of OxyContin —  
a prescription painkiller widely abused in the 1990s —  
has made it harder for users to alter that drug for  
inhalation or injection. As a result, they are switching from 
OxyContin to other drugs, including heroin. 
And although only about 10 percent of former OxyContin users 
have turned to heroin (the other 90 percent use other opiates,  
such as Vicodin or fentanyl), that statistic may be misleading.
“It sounds like a small number,” says Cicero, “but it’s a huge  
number relative to heroin users in this country. What’s more, 
we’re now seeing a migration of heroin and other dangerous 
drugs from the inner cities to the suburbs and rural areas.”
herointo
14  Washington University School of Medicine
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For the past three years, Cicero and  
colleagues have collected information from 
patients entering treatment for drug abuse. 
More than 2,500 patients from 150 treat-
ment centers in 39 states have answered survey 
questions about their drug use, with a focus on the 
reformulation of OxyContin. Results from those 
surveys were published in the July 12, 2012 issue 
of the New England Journal of Medicine.
The widely prescribed pain-killing drug origi-
nally was thought to be part of the solution to the 
abuse of opioid drugs because OxyContin (the 
brand name for the generic drug oxycodone) was 
designed to be released into the system slowly, 
thus not contributing to an immediate “high.” 
But creative drug abusers quickly figured out 
how to evade that mechanism by crushing the pills 
and inhaling the powder, or by dissolving the pills 
in water and injecting the solution, thereby getting 
an immediate rush as large amounts of the drug 
entered the system all at once.
Unlike “street” heroin, which varies in purity 
and is often laced with dangerous fillers by drug 
dealers, OxyContin came as advertised: Users 
knew the exact dosage they were getting and, in its 
slow-release form, that was a lot — as much as 15 
to 20 times more oxycodone than what comprised 
the normal immediate-release capsules.
In addition, from a psychological standpoint, 
many OxyContin abusers felt it wasn’t such a bad 
thing; after all, it was legal with a prescription and 
carried none of the stigma of heroin usage.
To combat these issues, the drug’s manufac-
turer introduced a new formulation of OxyContin 
in 2010. The new pills were much more difficult to 
crush and dissolved more slowly. The idea, accord-
ing to Cicero, was to make the drug less attractive 
to illicit users who wanted to experience an imme-
diate high. And it worked — sort of.
“Our data show that OxyContin use by inhala-
tion or intravenous administration has dropped 
significantly since the abuse-deterrent formulation 
came onto the market,” says Cicero, professor of 
neuropharmacology in psychiatry. “In that sense, 
the new formulation was very successful.”
However, although many users stopped using 
OxyContin, they didn’t stop using drugs.
“The most unexpected, and probably detri-
mental, effect of the new formulation was that it 
contributed to a huge surge in the use of heroin, 
which is like OxyContin in that it also is inhaled 
or injected,” Cicero says. “We’re now seeing 
reports from across the country of large quantities 
of heroin appearing in suburbs and rural areas.”
Cicero’s research into heroin began in the 1970s, 
when he and colleagues were studying the drug’s 
effects using animal models. They found — and 
later confirmed in human studies — that mor-
phine (to which heroin converts in the brain), 
depresses testosterone, the male sex hormone, 
leading to hypogonadism, a now well-recognized 
side effect of chronic opioid abuse.
So for 20 years, the investigators dealt mainly 
with young men from urban minority populations 
in their study of heroin, 
which at that time was 
essentially the only opi-
ate available for purchase 
on the street. In the 
1990s, with the emerging 
popularity of OxyContin, 
known as “hillbilly 
heroin” by its rural and 
suburban users, heroin 
suddenly had a director competitor.
Now Oxycontin’s formula change has left users 
in need of a substitute, and heroin has once again 
made tremendous inroads.
And although heroin abuse is a complicated 
issue, Cicero is frustrated by the government’s 
focus only on shutting down the supply of illegal 
drugs. Instead, he is more interested in the “why” 
of drug use, and current studies in his laboratory 
are examining risk factors for heroin and other 
opioid abuse to decrease the demand side of the 
supply-and-demand economic model.
“This trend toward increases in heroin use is 
important,” says Cicero. “As users switch to  
heroin, overdoses may become more common.  
We want to get the word out to physicians,  
regulatory officials and the public.”
Examining samples in the  
lab: Neuropharmacologist  
Theodore J. Cicero, PhD, and 
senior research coordinator 
Matthew S. Ellis, MPE
— THEODORE J. CICERO, MD
we’re now seeing repor
ts from
across the country of large
quantities of heroin  
in suburbs and rural areas
appearing
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I M A G I N A T I O N  may seem like a childhood dream,  
a mere glimpse of a gossamer vision of some wished-for reality.
But neurosurgeon Eric C. Leuthardt, MD, defines  
imagination somewhat differently. For him, imagination is  
where reality begins.
Leuthardt, associate professor of neurological surgery  
and neurobiology, is the director of the Center for Innovation  
in Neuroscience and Technology (CINT), a cross-disciplinary  
group within the Department of Neurosurgery that brings 
together experts from across Washington University to foster 
creativity and innovation.
That effort has proved fruitful. In the three years since 
its inception, CINT has engaged 32 clinical and non-clinical 
inventors, resulting in 47 ideas, 16 fellowships and 12 patents — 
for which seven have been licensed to industry. 
Cross-connections — validating the science, demonstrating 
that a new medical procedure brings value to patients, accessing 
new markets in industry, and resonating with the zeitgeist of 
humanity — are vital to the success of any invention. 
The CINT provides an effective, ethical framework for these 
considerations. But for Leuthardt, everything circles back to 
envisioning the future.
“Anything that can be imagined can be done,” he asserts.  
“The challenge is to imagine how the world can be different,  
and then the world figures out a way to make that happen.”    
C O N T I N U E D  O N  P A G E  2 0  »
R O B O T I C  
A R M  can be  
controlled  
directly by  
the brain
B O N E  G R O W T H 
S T I M U L A T O R  
to speed healing
A D V A N C E D  B R A I N 
R E T R A C T O R  
for safer surgeries
  Promise the  
FUTURE
 New hope for tomorrow — designed, built, 
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I M A G I N A T I O N  may seem like a childhood dream,  
a mere glimpse of a gossamer vision of some wished-for reality.
But neurosurgeon Eric C. Leuthardt, MD, defines  
imagination somewhat differently. For him, imagination is  
where reality begins.
Leuthardt, associate professor of neurological surgery  
and neurobiology, is the director of the Center for Innovation  
in Neuroscience and Technology (CINT), a cross-disciplinary  
group within the Department of Neurosurgery that brings 
together experts from across Washington University to foster 
creativity and innovation.
That effort has proved fruitful. In the three years since 
its inception, CINT has engaged 32 clinical and non-clinical 
inventors, resulting in 47 ideas, 16 fellowships and 12 patents — 
for which seven have been licensed to industry. 
Cross-connections — validating the science, demonstrating 
that a new medical procedure brings value to patients, accessing 
new markets in industry, and resonating with the zeitgeist of 
humanity — are vital to the success of any invention. 
The CINT provides an effective, ethical framework for these 
considerations. But for Leuthardt, everything circles back to 
envisioning the future.
“Anything that can be imagined can be done,” he asserts.  
“The challenge is to imagine how the world can be different,  
and then the world figures out a way to make that happen.”    
C O N T I N U E D  O N  P A G E  2 0  »
N O N - I N V A S I V E  
B R A I N  S I G N A L S  
facilitate stroke rehab
B R A I N - C O N T R O L L E D 
H A N D  O R T H O T I C S  
to speed stroke recovery
  Promise the  
FUTURE
A CINT team meets regularly to discuss testing results.
Ray MaRklin
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  Effective 
Creativity
Building ideas  
into medical  
breakthroughs
Never has there been such potential to improve human health through technological innovation. However, financing, regulations and the need for 
broad expertise makes innovation challenging. The Center 
for Innovation in Neuroscience and Technology (CINT) 
devises collaborative strategies for navigating the journey 
from an “Aha! moment” to a new medical technology.
generation
Experts in medicine, science, 
engineering, law, business and  
finance convene at “Invention 
Sessions” where they discuss clinical 
needs, emerging technologies and 
market opportunities. These aren’t 
classes, but participants do get 
“homework”: assess the clinical 
problem, the novelty and feasibility of 
the idea, and the size of its potential 
market. The experts reconvene to 
refine various concepts, rank them 
in order of their potential, and 
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Building ideas  
into medical  
breakthroughs
evaluation validation translation
Each idea earns a chance to shine 
in the spotlight under the scrutiny 
of the CINT’s executive committee 
as it considers a range of real-world 
questions. Does research support 
the merits of an idea? Is it really 
better than any new or existing 
technologies? Is it novel enough for 
licensing? Would the market adopt 
it? How long, difficult and costly 
will the regulatory approval be? 
Some ideas are rejected; some are 
modified. The top ideas are assigned 
to innovation teams.
Innovation fellowship teams, 
composed of faculty and students 
from neurosurgery and engineering, 
develop rough concepts into working 
prototypes. Teams establish clinical 
and medical specifications, draft 
engineering designs, and create 
working physical prototypes.  
Along the way, physicians learn  
about mechanical, legal and 
industry-related 
issues; engineers gain 
an understanding of 
clinical nuance.
CINT embodies a transformation 
of academic culture, fostering 
experimental creativity, 
entrepreneurial activity and 
collaborative enterprise. Thinking 
“outside the box “ will deliver more 
advanced biomedical technology  



















$100A “Death Valley” gap between 
public and private support for 
costly device research discourages 
inventors. CINT bridges this gap 
by working with investors to 
target worthy ideas — speeding 
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The past 100 years has created an impressive track record of 
how imagining can lead to new realities, says Leuthardt, who 
also is an associate professor of biomedical engineering and 
of mechanical engineering and materials science.
From commonly used technologies such as instant  
messaging and Skype to more esoteric military applications 
such as Lockheed Martin’s HULC (human universal load  
carrier), imagination is the catalyst of invention.
At the CINT, Leuthardt and colleagues focus on creating  
new technology to serve neurosurgery. By formalizing rela-
tionships among the School of Medicine’s Department of 
Neurosurgery, the School of Engineering and the Office of 
Technology Management, collaborators at the center hope to 
foster creativity and streamline the process of scientific and 
technical innovation and real-world application.
Much of the work being done at the CINT is focused on 
technologies that can impact care of patients with neurologic 
disease. This ranges from the creation of specialized devices 
to the more fundamental fields of neuroprosthetics, motor 
physiology, speech physiology, epilepsy and stroke rehabilita-
tion. The technologies that have emerged have encompassed 
a broad range, including implantable sensors to treat hydro-
cephalus, novel coatings of orthopedic hardware to facilitate 
bone growth, and engineering solutions for stroke.
The idea of a brain-computer interface has been a flag-
ship technology and scientific endeavor of the CINT. Indeed, 
many of the inventions developed or under consideration are 
related to issues of restoration, enabling people with spinal 
cord injuries or who have had a stroke to regain function.
“That’s where we begin, but it’s not where we end,” says 
Leuthardt. “As a physician, it’s critical to restore function to 
people with motor disabilities — that’s absolutely vital. But 
that is Chapter 1 of how we see ourselves, what we think our 
limitations are. Maybe our ability to interact with the world 
no longer stops with our fingertips and bodies, in a real way.”
Fundamentally, Leuthardt hopes to change how humans 
interact with machines. Although that might sound like  
science fiction, neuroprosthetics — devices linked to the 
brain that allow patients to move a robotic arm or a cursor 
on a screen simply by thinking about doing so — already 
exist. According to Leuthardt, this type of technology will 
one day be as commonplace as the video games of today.
“My job is to make it boring,” he says. “We may get 
excited about the new iPhone 5, but we don’t get excited by 
our DVD players anymore. Similarly, neuroprosthetics, body 
modulation and cognitive capability will one day no longer 
inspire awe at the magnitude of the technical accomplish-
ment; they will just be a part of everyday life.”
Another key area of study at the CINT is brain mapping. 
Leuthardt and his colleagues are developing advanced tech-
niques to locate and preserve critical areas of brain function.
During any neurological surgery, a key concern is not 
doing any harm to the brain while fixing a problem, such as 
operating on tumors or areas affected by epilepsy. Currently, 
neurosurgeons are able to watch the brain “light up” in real 
time during surgery as participants perform tasks such as 
talking or moving their hands. However, this process occurs 
during “awake” surgeries, something Leuthardt would like  
to change. New technology in development will allow neuro- 
surgeons to assess critical brain areas — such as those 
devoted to speech and motor function — by monitoring the 
specific electrical signatures of various brain networks while 
the patient is anesthetized.
This type of breakthrough, which benefits patients by 
removing a risk for serious injury, is an example of the type 
of inventiveness the CINT hopes to foster. By providing 
an institutional structure that brings together people from 
diverse backgrounds — medicine, engineering, computer 
science, physics, chemistry, mathematics, nanotechnology,  
law and business — the CINT promotes collaboration, 
allowing innovation teams to generate ideas that none of the 
individuals would have been able to create by themselves. 
“The world’s become a more complex place,” Leuthardt 
explains. “All of these fields have become very subspecialized. 
The benefit is that it gives us expertise in that subspecialty, 
but it’s also a worldview that can stymie creativity.”
However, he says, if a neurosurgeon and an engineer sit 
down to talk, it’s likely the interaction will lead to non-lin-
ear, unexpected conclusions. A physician may learn about an 
existing technology — something that is very exciting to the 
engineer — that would solve a particular medical problem.
“Eric has been successful in creating a wonderful  
collaborative research environment within the Department 
of Neurosurgery,” says Ralph G. Dacey Jr., the Henry G. 
and Edith R. Schwartz Professor and head of neurological 
surgery. “The Center for Innovation in Neuroscience and 
Technology has facilitated the development of several break-
through neuromedical technologies.”
Finally, Leuthardt emphasizes that the academic and 
medical cultures can be inhospitable to creativity in that 
they often do not allow for trial-and-error thinking. In the 
creative process, he asserts, it is acceptable, and perhaps even 
desirable, to make and learn from mistakes.
“Education and expertise can be limiting,” says Leuthardt. 
“We need to be humble about our knowledge so that we can 
learn from other people. Innovation, more than ever, comes 
out of good relationships with other people.”
Electrodes monitor brain 
activity (red) as a patient 
responds during “awake” 
surgery. By comparison, 
new technology will allow 
neurosurgeons to monitor 
the brain while a patient is 
under general anesthesia, 
providing a more efficient 
and safer way to identify 
and preserve critical areas  
of the brain.
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PitchPerfect
Introducing good people
and their great ideas
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That’s the idea behind IdeaBounce, a campus-
wide initiative founded in 2003 to support student, 
faculty and community interest in commercial, 
social, global, technological, legal, artistic and 
intellectual entrepreneurship.
IdeaBounce is the brainchild of Washington 
University’s Skandalaris Center for Entrepreneurial 
Studies. This past October, for the first time, an 
IdeaBounce was held at the School of Medicine.
“The time went so fast, and you’re so nervous,” 
says Dana M. Watt, a graduate student in anatomy 
and neurobiology in the Division of Biology and 
Biomedical Sciences. “But I think the judges liked 
my idea, and maybe someone will help me take it 
to the next level.”
They did. Watt and four others among the 13 
people who made pitches were named the event’s 
five winners (see WINNING PITCHES, page 23). 
As a reward, the winners each received a check 
for $50 and the opportunity to spend one-on-one 
time with the judges at a dinner after the event.
Credit for bringing the IdeaBounce competition  
to the School of Medicine goes to members of the 
BioEntrepreneurship Core (BEC), a group of the 
school’s graduate and medical students, post- 
doctoral researchers and faculty who share an 
interest in entrepreneurship. 
“The university is working hard at empha-
sizing entrepreneurship,” says Hugh Bender, a 
fourth-year doctoral student in developmental, 
regenerative and stem cell biology and president 
of the BEC. “On the medical school campus, the 
National Institutes of Health invests millions of 
dollars in research. But what’s the output of that?
“In academia, it’s typically peer-reviewed,  
published papers,” he says. “A lot of that research 
could also be commercialized; ideas are getting 
lost because we don’t think in terms of intellectual 
and translational property. We want to focus on 
the fact that researchers are creating value, which 
should be recognized beyond publications alone.”
Started in 2004, the BEC now boasts a mailing 
list of more than 300. The group fosters conversa-
tions and idea-sharing through a series of events 
throughout the year, including panel presentations 
by community entrepreneurs and Washington 
University faculty and staff. 
The BEC also holds casual morning coffee  
lectures and get-togethers, all with the goal of  
creating interest in entrepreneurship.
“The BEC represents an opportunity to network 
and meet different people in industry,” says Rachael 
A. Hansel, a postdoctoral researcher in radiation 
oncology. “As a student or postdoc, you are highly 
focused on science and that millimeter slice of the 
world. I’m looking for jobs, so here you can meet 
creative people, bounce ideas and open up your 
view of the world and your career possibilities.”
The BEC is a “cohesive nucleus of energy” that 
contributes to the culture of entrepreneurship now 
blossoming at the medical school, says Kenneth A. 
Harrington, managing director of the university’s 
Skandalaris Center for Entrepreneurial Studies.
 “You don’t know if an idea is viable until you 
act entrepreneurially,” says Harrington. “The 
reason IdeaBounce is so important is that it helps 
people with ideas meet other people who can help 
move their ideas forward. In that process, we 
develop the idea-makers into entrepreneurs. Once 
they learn that, they have that skill for life.”
IdeaBounce offers participants a “speed-dating” 
style of competition in which they have just two 
minutes to pitch a creative, innovative idea to a 
panel of judges. The medical school’s IdeaBounce 
No notes, no props, no polished PowerPoint presentation.  
Just two minutes — 120 seconds — of passion and persuasion.1 2 0
SECONDS
Student leaders of the School of Medicine’s BioEntrepreneurship 
Core, clockwise from lower left: Dana M. Watt, secretary;  
Hugh Bender, president; Matthew C. Hibberd, vice president; 
Sriram Devanathan, vice president; Aswin J. Mathews,  
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participants, who could present medical, life  
sciences or unrelated ideas, were judged on three 
essential criteria: clarity of the idea, the passion of 
the presenter, and whether they clearly requested 
help. Within 45 minutes after IdeaBounce started, 
the judges had identified the top five competitors.
“I thought all of the ideas were good,” says 
judge Pete Peters, executive director of Innovate 
Venture Mentoring Service, a local organization 
that provides free, team-based mentoring of new 
ventures by business and entrepreneurial leaders. 
Peters, who teaches an annual course, Origins of 
Bioentrepreneurship, at the medical school, says 
becoming an entrepreneur is a learned skill.
“We really need to foster this spirit of entre-
preneurship,” he says, “so that people feel comfort-
able about pursuing ideas and creating a viable 
business or product. There are so many resources 
at Washington University and around St. Louis 
that can help people bring an idea to reality.”
The university already has delved into large-scale 
bioentrepreneurial collaboration around St. Louis.  
It is a founding member, along with other area uni-
versities, of the Center of Research, Technology  
and Entrepreneurial Exchange (CORTEX), which 
strives to establish the region as an international bio-
sciences powerhouse. In another effort, BioSTL, the 
university — with BJC HealthCare and the St. Louis 
Life Sciences Project — is working to 
spur bioscience company creation and 
drive economic growth.
“Washington University recognizes the need 
and opportunity to expand its research culture, to 
foster research innovation and entrepreneurship in 
addition to knowledge creation and publication,” 
says Evan D. Kharasch, MD, PhD, vice chancellor  
for research. “Turning research discoveries into 
products and services, so that the public can bene-
fit from our research, is a major institutional goal.”
The BEC is aggressively expanding its presence, 
co-hosting interdisciplinary discussions on entre-
preneurial topics with Washington University’s 
other schools, such as law and business. 
“It’s a culture that is shifting toward innovation 
and bringing ideas to a practical endpoint,” says 
Elizabeth A. Germino, an MD/PhD student in  
the university’s Medical Scientist Training 
Program. “In medicine and science, you need  
collaborations and expertise. One of the strengths 
here is the collaborative atmosphere, but, as  
students, we’re so focused on what we need to do 
to learn our jobs that we may miss essential skills, 
such as how to clearly present an idea, pursue it, 
and ask for help and resources. The BEC is a  
way to learn that from like-minded people.  
IdeaBounce makes it fun.”
I D E A  
A new spirometer design
P R E S E N T E R  
Andrew J. Brimer, graduate 
student in engineering 
P I T C H
Spirometers measure lung  
function, but are expensive, 
ranging from several hundred  
to thousands of dollars each.  
A new, award-winning proto-
type would cut the production 
cost to less than $10.
N E E D S  
Mentors, investors, product 
development
I D E A  
Using miRNAs (micro RNAs)  
to diagnose lung cancer
P R E S E N T E R
Thomas L. Cohen,  
postdoctoral research scholar  
in genetics
P I T C H  
By developing an assay using 
miRNAs, lung cancer can be 
diagnosed more accurately and 
cheaply than current methods. 
N E E D S  
Team members, mentors,  
investors, and legal, financial 
and accounting advice
I D E A  
Mobile drug database app
P R E S E N T E R  
Paul G. Gamble, first-year  
medical student
P I T C H  
A mobile app will enable 
patients to determine out-of-
pocket costs for various drugs 
and then identify comparable 
cheaper medications. This will 
aid in making value-based 
treatment decisions.
N E E D S  
Mentors, legal advice,  
advisors, investors
I D E A  
Genotyping to determine  
compatibility on dating website
P R E S E N T E R  
Masatoshi Kaneko, graduate 
student in biomedical  
engineering and business
P I T C H
Adding geno-typing could 
enhance a suitable match  
based on intelligence and  
personality in addition to  
subjective preferences.
N E E D S  
Mentors, legal advice,  
strategic development 
I D E A  
Online expert database  
for scientists
P R E S E N T E R  
Dana M. Watt, graduate student 
in anatomy and neurobiology
P I T C H  
To more cost-effectively  
allocate limited research dollars, 
an online database will share 
scientific expertise and  
experiments.
N E E D S  
Team members, advisors,  
IT, legal advice, operations  
and management
No notes, no props, no polished PowerPoint presentation.  
Just two minutes — 120 seconds — of passion and persuasion.
Students met at a recent 
coffee lecture to talk with 
Kenneth A. Harrington,  
managing director of the  
university’s Skandalaris Center 
for Entrepreneurial Studies.
W I N N I N G  P I T C H E S      Promising ideas from the School of Medicine’s IdeaBounce
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The urgent need to discover the causes of the most common diseases and 
to apply this knowledge to successful treatments has never been greater. 
An aging population in America — and a growing underserved population 
worldwide — have pushed traditional health care delivery to a breaking point.
 The solutions are complex, and yet for Washington University  
School of Medicine, the action is straightforward. Our mission is to lead  
in the advancement of human health. We must train the next generation  
of medical leaders. We must martial our extraordinary scientific resources  
to eliminate entire diseases and find treatments that improve and prolong  
lives. And, ultimately, we must take major steps to improve our efficiency  
in streamlining health care delivery, reducing unnecessary costs, and  
serving populations in need.
 Fortunately, our School 
of Medicine is one of the few 
institutions — anywhere — with 
the vision, depth of experience, 
and combined intellect required  
to do what can and must be  
done to advance human health. Through innovative research, outstanding  
clinical care, and the forward-thinking education of tomorrow’s leaders  
in medicine, we have achieved international prominence.
 Yet, the task is great — so great, in fact, that it is easy for us  
to question how an individual can have the ability to make a significant 
difference. However, there is no question that every gift matters. 
We invite you to be a part of a historic endeavor:  








In the 20th century, we changed the understanding of medicine.  
In the 21st century, we are transforming the very meaning of medicine. 
Advancing human health through the 
Campaign for Washington University
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A major, multi-year fundraising initiative, Leading 
Together: The Campaign for Washington University, 
has been announced by Washington University in 
St. Louis to build on its strong history and further 
evolve the university’s global leadership.
At the School of Medicine, that translates to 
leveraging our strengths throughout the university 
to develop techniques and treatments necessary to 
help ever-greater numbers of people throughout 
the world to live better and longer than previously 
thought possible.
“From helping our neighbors take control of 
their health to providing cures in countries where 
people are still dying from easily treatable diseases, 
the faculty, students, and alumni of our School 
of Medicine will continue to pursue new ways to 
save and improve lives,” says Chancellor Mark 
S. Wrighton. “With the support of our alumni, 
parents, friends, corporations, and foundations, 
we can build upon the accomplishments of recent 
decades and contribute even more significantly  
to our communities, our nation, and the world.”
Medical school campaign priorities
The campaign’s four themes — preparing the 
leaders of tomorrow, advancing human health, 
inspiring innovation and entrepreneurship, and 
enhancing the quality of life — will be the focus of 
School of Medicine efforts during the campaign.
To succeed in each of these areas, fundraising 
targets for five priorities have been identified:
 n to attract and retain outstanding faculty:  
$240 million
 n to attract a talented and diverse student 
body: $40 million
 n to advance the scholarship, research, and 
creative potential of students and faculty:  
$750 million 
 n to further strengthen an exceptional  
teaching, research, and working environment: 
$40 million
 n to enhance excellence throughout the school 
by increasing unrestricted annual support: 
$30 million
“Our overarching vision is to use our resources 
as a top-tier institution to make significant and 
lasting contributions to advancing human health,” 
says Larry J. Shapiro, MD, executive vice chancellor 
for medical affairs and dean. “To meet these chal-
lenges, we must gather resources and make broad 
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Local and global community outreach
Actively engaged in neighborhood clinics, schools, 
and community organizations that promote well-
ness, the faculty, students, and staff of the School of 
Medicine regularly volunteer clinical services in
underserved areas of St. Louis, the United States, 
and at a growing number of international locations. 
Through these efforts, Washington University has 
demonstrated an unwavering commitment to the 
discovery of knowledge and the advancement of 
medical research and patient care.
Partnering for success
Washington University School of Medicine is a 
leading center for teaching, research, and patient 
care and is well-known for its tremendous innova-
tion in genomics, neuroscience, imaging, infectious 
diseases, cardiology, and biomedical engineering, 
consistently ranking among the world’s finest  
medical institutions.
Yet our potential for even greater leadership 
is much stronger than previously imagined, and 
we have never been more committed to expand-
ing upon these great strengths. To this end, we 
view the School of Medicine’s prospects for the 
advancement of medicine to be virtually limitless.
With the generous support of the alumni and 
friends who share our aspirations, our ideals, and 
our spirit, we can forge a stronger foundation for 
the future. Please join us as we educate and inspire 
the next generation of outstanding students in our 
unwavering determination to make ever-greater 
contributions toward improving human health on 
a global scale.
Groundbreaking scientific discoveries over 
the past century have established the School of 
Medicine’s reputation as one of the great medical 
centers in America and throughout the world.  
The depth and breadth of scientific inquiry 
addressed by its researchers has a national and 
global impact, and its multi-pronged approach 
to research holds tremendous promise for rapid 
advances in deciphering fundamental causes of 
diseases. Ultimately, research conducted at the 
School of Medicine is transforming medicine, 
leading to better therapies and therapeutics.
Attracting the best students and faculty
For the past 14 years, Washington University  
has recruited the top class of entering medical  
students in the country, and scholarships are 
critical to this success. The School of Medicine’s 
Programs in Occupational Therapy, Physical 
Therapy, and Audiology and Communication 
Sciences rank among the top three programs  
in each of their respective fields nationally. 
Signature graduate education programs in the 
Division of Biology and Biomedical Sciences and 
the Medical Scientist Training Program set the  
bar for peers. Likewise, residents and fellows at  
the school and our affiliated hospitals are among 
the best in the world.
Central to our continuing success is one of the 
world’s great medical faculties. In an increasingly 
competitive environment for engaging the best
academicians, endowed professorships play 
an important role in recruiting and retaining 
the most important resource of the School of 
Medicine: the extraordinary people who lead the 
field in teaching and research. Increasing our 
number of endowed professorships is essential  
to our leadership position in the field.
Recognizing our clinical physicians
Most importantly, School of Medicine physicians 
save lives — and directly work to improve the  
quality of life for tens of thousands of patients  
each year. With its hospital partners on the 
Washington University Medical Center campus 
— Barnes-Jewish Hospital and St. Louis Children’s 
Hospital — the School of Medicine is committed to 
providing the greatest level of healing in the world. 
From the most fragile infants to individuals with 
extremely rare diseases, physicians provide each 
patient with medical expertise that is grounded in 
the finest training possible. Working together,  
medical teams are skilled in innovative techniques 
and fully immersed in compassion for humankind.
Leading Together The Campaign for Washington University
“We believe answering 
the great questions in 
medicine requires bold 
research focused in areas 
of high reward. The time 
for answers is now. Every 
individual can help us 
find them. Together, we 
will make a difference.”
Larry J. Shapiro, MD
Executive Vice Chancellor for 
Medical Affairs and Dean 
• Understanding the Brain
• Cancer and Personalized Medicine
• Diabetes, Heart Disease, and Obesity
• Infectious Diseases and Global Health
• The Next Generation
• The Annual Fund
Learn more: medicalalumni.wustl.edu
The following pages summarize key areas in which  
support is needed to advance human health:
125193_MAD_24-36_CS5.indd   27 12/13/12   9:57 AM
Winter 201228  Washington University School of Medicine
Together, 
   we discover.  
TH E  H U M A N  BR A I N remains a critical frontier in modern-day medicine. 
Brain diseases devastate millions 
of families through loss of 
life, cognitive and emotional 
disability, social and financial 
instability, and fear. Washington 
University is at the forefront of 
discovery and treatment in  
neuroscience. Our enduring 
partnerships with alumni, 
friends, and philanthropists 
allow us to advance the field, 
simultaneously providing 
treatment to patients in need 
and influencing the healing of 
others throughout the world. 
n With more than 17,000 new cases 
of malignant brain tumors diag-
nosed each year, the Department of 
Neurological Surgery is developing 
new approaches and clinical trials.
n Scientists and physicians at the 
Intellectual and Developmental 
Disabilities Research Center provide 
the latest research to families of chil-
dren with developmental disabilities.
n Washington University has been 
chosen by the National Institutes of 
Health (NIH) to lead a consortium  
of research institutions in the  
Human Connectome Project, a bold 
effort to map the human brain. 
n The Washington University 
Neurofibromatosis Center in the 
Department of Neurology is the  
largest and most comprehensive  
center of its kind in the world.
Together, we can
n fund clinical trials in Alzheimer’s  
disease and advance our leadership  
in Alzheimer's and related disorders.
n develop drugs to treat mental illness. 
n discover treatments for childhood  
disabilities.
Areas of excellence
n The Charles F. and Joanne Knight 
Alzheimer’s Disease Research Center 
(Knight ADRC) is internationally 
known for leadership in the field. 
Researchers at the Knight ADRC not 
only developed the standard clinical  
measure for staging of dementia, 
but also established that Alzheimer’s 
disease begins damaging the brain 
decades before the first appearance 
of outward symptoms.
n The Taylor Family Institute for 
Innovative Psychiatric Research in  
the Department of Psychiatry is 
advancing the science underlying  
the diagnosis and treatment of  
psychiatric illnesses.
n At the Hope Center for Neurological 
Disorders, more than 500 scientists 
are devoted to discovering funda-
mental causes of neurological 
disorders such as Alzheimer’s and 
Parkinson’s diseases, multiple sclerosis, 
and amyotrophic lateral sclerosis  
(ALS, or Lou Gehrig’s disease).
Washington University researchers 
are committed to studying the 
human brain across the life span. 
Terrie E. Inder, MD, PhD, studies 
neurodevelopmental outcomes of 
newborn infants.
Understanding the Brain
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AS A LEADER  in     diagnosis, treatment,         and prevention, the 
Alvin J. Siteman Cancer Center 
at Barnes-Jewish Hospital 
and Washington University 
School of Medicine is driving 
an ever-greater convergence 
among oncology, genomics, 
imaging, and pathology. Its 
interdisciplinary approach 
to translating laboratory 
findings into comprehensive, 
compassionate patient care 
will ultimately foster the 
development of personalized 
medicine for cancer and  
other diseases.
n The Department of Radiation 
Oncology works with units across 
the entire medical enterprise on the 
development and implementation of 
new cancer treatments. The recent 
acquisition of the Midwest's first pro-
ton accelerator allows physicians to 
target tumors with greater precision 
and minimize radiation of vital organs 
and tissues surrounding tumors.
n Genomics and Pathology Services 
(GPS), a collaborative effort between 
the Department of Pathology and 
Immunology and the James S. 
McDonnell Department of Genetics, 
provides expertise in genetic testing 
and pathology consultation, including 
clinical genomics and next-generation 
sequencing.
Together, we can
n develop tests to detect cancer at its 
very beginnings and to assess genetic 
cancer risk.
n identify and evaluate strategies for 
stopping cancer growth or preventing 
it altogether.
n lead the nation in research and  
treatment of multiple myeloma.
Areas of excellence
n Led by investigators in the 
Department of Medicine’s Division of 
Oncology, collaborative and creative 
research seeking to uncover causes 
and cures for cancer takes place in 
nearly all departments and divisions 
throughout Washington University 
School of Medicine. The division also 
has joined with several institutions in 
creating a protein atlas.
n The Genome Institute has helped to 
define and understand the makeup of 
the human genome in myriad ways, 
including contributing 25 percent of 
the finished sequence to the Human 
Genome Project. This effort informs 
other research, including successfully 
decoding — for the first time in  
history — the complete DNA of a  
cancer patient by tracing her dis-
ease, acute myelogenous leukemia, 
to its genetic roots. In sequencing 
the patient’s entire genome and the 
genome of her leukemia cells, inves-
tigators were able to identify the 
genetic changes unique to her cancer. 
In addition to its hope for saving lives, 
this work promises to accelerate the 
era of personalized medicine.
The Alvin J. Siteman Cancer Center, 
led by Timothy J. Eberlein, MD, 
the Spencer T. and Ann W. Olin 
Distinguished Professor, is a  
beacon of hope for cancer patients 
and their families.
Cancer and Personalized Medicine
Together, 
   we lead.  
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Together, 
   we innovate.  
HEART DISEASE, affecting more  than 82 million 
Americans, is the leading cause 
of death in the United States 
for adults. In addition, heart 
disease is the leading cause of 
complications and death for 
two-thirds of the 25 million 
people with diabetes in this 
country. Obesity plays a major 
role in both diseases in adults 
and children. Researchers 
are tackling these combined 
problems by providing clinical 
treatment and conducting 
scientific studies throughout 
the School of Medicine in more 
than a dozen multidisciplinary 
programs and centers. 
n The Cardiovascular Division has 
emerged as a national leader in 
both research and delivery of high-
quality cardiovascular care to a large 
patient population. Faculty mem-
bers in the division have conducted 
groundbreaking research in the area 
of dissolving blood clots for acute 
myocardial infarction, biomarkers for 
cardiac injury, and cardiac imaging.
n The David Goldring Division of 
Pediatric Cardiology and its partner, 
St. Louis Children’s Hospital, have 
been recognized for more than a half-
century for innovative approaches to 
infants and children with congenital 
heart disease. This reputation contin-
ues today with the division's recogni-
tion as a national leader in the area of 
heart failure and transplantation.
Together, we can
n partner with start-up companies to 
develop drugs for heart disease.
n identify defects that underlie many  
of the world’s most important dis-
eases, including heart arrhythmias, 
diabetes, and epilepsy. 
n identify new therapies for heart and 
vascular disease in diabetes.
Areas of excellence
n At the Diabetic Cardiovascular Disease 
Center (DCDC), investigators are work-
ing toward a better understanding 
of the underlying basis connecting 
diabetes and heart disease. 
n The School of Medicine is a world-
class center for research, educational, 
and clinical care programs in atrial 
fibrillation, minimally invasive cardiac 
surgery, aortic surgery, ventricular-
assist devices, and heart transplant.
n Innovative research, along with  
successful treatments and education 
programs, is changing lives at the 
school’s Human Nutrition Center.
n Patient care and research in diabetes  
are advancing on multiple fronts: 
understanding and treating child-
hood diabetes by the Department of 
Pediatrics, significant advances within 
the Department of Medicine’s Division 
of Endocrinology, genetic studies 
on type 1 diabetes at The Genome 
Institute, and research into electric 
signaling in tissues at the Center 
for the Investigation of Membrane 
Excitability Diseases (CIMED).
Douglas L. Mann, MD, the Tobias and 
Hortense Lewin Distinguished Professor 
of Cardiovascular Diseases, leads the 
university’s participation in a national heart-
failure research network sponsored by the 
National Institutes of Health (NIH).
Diabetes, Heart Disease, and Obesity
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IMPROVING GLOBAL HEALTH  is among    the world’s most pressing 
challenges, and infectious 
diseases research has become 
one of the largest areas of 
concentration within the 
School of Medicine. As new 
diseases appear, there is an 
ever-greater risk of rapid 
transmission and spread of 
infection. By traveling to  
foreign countries to provide 
basic health care or by 
offering programs in St. Louis 
aimed at preventing sexually 
transmitted diseases, our 
faculty, students, and staff 
are dedicated to making 
a difference — locally, 
nationally, and globally.
n With support from the Bill and 
Melinda Gates Foundation, research-
ers hope to reduce suffering caused 
by two tropical diseases: onchocer-
ciasis (river blindness) and lymphatic 
filariasis (elephantiasis). By optimizing 
simple and cost-effective treatments 
already being used to help hundreds 
of millions of people, the researchers 
seek to provide treatment for many  
neglected tropical diseases.
n Washington University’s scope of  
work in this broad field includes 
patient safety, reduction of hospital-
acquired infection incidence rates, 
community outreach, and the  
establishment of a Midwest Regional 
Center of Excellence for Biodefense 
and Emerging Infectious Diseases 
Research. 
Together, we can
n effectively prevent and treat infectious 
diseases of the urinary and reproduc-
tive tracts to alleviate suffering of 
women and children worldwide.
n recognize commonalities among 
diseases and, where possible, apply 
effective solutions broadly.
n explain diseases not yet known to be 
related to infection.
Areas of excellence
n Children are disproportionately 
affected by infectious diseases, as  
well as by malnutrition. In an effort  
to cost-effectively reduce the  
malnutrition rate and reverse the 
cycle of poor health standards and 
lower educational achievements 
associated with it, School of Medicine 
researchers have developed ready-to-
use therapeutic foods (RUTFs) that  
can be locally manufactured, easily 
stored without refrigeration, and  
successfully used to ensure proper 
nutrition for children.
n The study of the human microbiome 
promises to provide a better road 
map for investigating what goes  
awry in diseases thought to have 
microbial links and determining why 
the dangerous pathogens residing 
within us do not always cause life-
threatening illnesses.
n Washington University has been 
selected by the federal Centers for 
Disease Control and Prevention to 
develop and test new approaches  
for reducing health care-associated 
infections.
Mark J. Manary, MD, the Helene B. 
Roberson Professor in Pediatrics,  
and colleagues have worked for 
nearly two decades to reduce  
childhood malnutrition.
Infectious Diseases and Global Health
Together, 
   we heal.  
Diabetes, Heart Disease, and Obesity
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IN  M E D I C I N E, knowledge, experience,     and inspiration is passed 
from one generation to the 
next in a grand continuum. 
Washington University is 
committed to providing its 
students with a rigorous 
foundation in science, 
advancing the tools needed 
to diagnose and treat patients, 
and developing the ethical 
basis for making critical 
decisions in a rapidly changing 
health care environment. 
Attracting the best students 
and faculty, with the support of 
alumni and friends, represents 
a partnership for the future. 
n The partnerships our faculty and 
students form with our generous 
donors are often warm and enduring. 
Endowed professorships can serve as 
the foundation for lifelong collabora-
tion between faculty and donors in 
the advancement of medicine. The 
joy of providing a student scholarship, 
meeting the student who receives 
it, learning about the student’s aspi-
rations, and knowing that one has 
played an important role in shaping 
the future of medicine can be very 
rewarding for donors. For students, 
this relationship often inspires them 
to make a commitment to continue 
the tradition of philanthropic support 
when they are positioned to do so.
Together, we can
n recruit and empower the brightest 
faculty and most gifted and creative 
graduate students.
n advance our leadership in both  
innovative learning methods and  
in adapting teaching resources to 
meet the changes in medical  
knowledge and practice.
Areas of excellence
n To secure the future of our leader- 
ship in medical education, it is 
imperative to increase the number of 
endowed professorships for clinical 
and basic science faculty, as well as 
professorships for preceptors, those 
clinicians who provide hands-on  
training to students. An endowed  
professorship is often a crucial factor 
in an individual’s decision to join the  
School of Medicine faculty. These  
professorships — which provide  
support for salary, benefits, and 
research needs — are central to 
retaining our most promising faculty 
and recruiting stellar outside leaders.
n We continue to seek support for 
scholarships to address the cost of 
education, reduce debt upon gradu-
ation, and recruit the best students. 
Medical, occupational therapy, physi-
cal therapy, and audiology students 
have been the primary beneficiaries 
of these scholarships; we are extend-
ing our efforts to include students 
in the Medical Scientist Training 
Program and the Division of Biology 
and Biomedical Sciences.
Teaching and inspiring: David J. 
Murray, MD, the Carol B. and Jerome 
T. Loeb Professor of Anesthesiology, 
helps students develop good 
judgment and problem-solving 
diagnostic skills in the Howard and 
Joyce Wood Simulation Center.
The Next Generation
Together, 
   we learn.  
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THE ANNUAL FUND provides essential support for scholarships, 
seed funding for initiatives that 
sustain intellectual vitality, and 
resources to respond to new 
opportunities and challenges. 
Unrestricted annual giving 
empowers the leaders of the 
School of Medicine to support 
its highest priorities, allowing 
the university to maintain its 
margin of excellence. Every  
gift matters; growing our 
Annual Fund participation  
has never been more critical.
n Many former house staff and fellows 
support the Annual Fund within the 
departments and divisions in which 
they trained. Their generosity funds 
resident education, research, training, 
and special projects.
n The local community benefits from 
a wide range of student-initiated 
projects. More than 40 of these have 
been funded with help of unrestricted 
annual gifts. 
n The school’s Programs in Physical 
Therapy, Occupational Therapy, 
and Audiology and Communication 
Sciences also benefit from gifts to the 
Annual Fund. Most gifts are directed 
to student support.
Together, we can
n support the eight out of 10 medical 
students who need financial  
assistance.
n support student programs that  
benefit the community.
n provide alumni endowed professorships.
n provide key resources throughout  
the School of Medicine.
Areas of excellence
n In recent years, reunion class giving 
has become increasingly important. 
Each year, class gifts to the Annual 
Fund provide either fully endowed 
scholarships or annually funded  
scholarships, honoring the philan-
thropy of each class gift. Thus far,  
23 alumni classes have endowed 
scholarships benefitting 231 students.
n Annual Fund gifts from medical  
student and house staff alumni  
are divided among scholarships,  
student programs, alumni endowed 
professorships, and other high  
priorities of the dean.
n School of Medicine faculty are among 
the most committed supporters. Since 
2010, current and former faculty have 
provided nearly 40 annual scholarships, 
demonstrating their commitment to 
our students and, most significantly, 
to addressing the complexity and cost 
of a comprehensive 21st-century 
medical education.
Outstanding teacher and 
mentor Jeffrey I. Gordon, 
MD, the Dr. Robert J. Glaser 
Distinguished University 
Professor, with trainees in  
his laboratory. 
The Next Generation The Annual Fund
Together, 
   we advance.  
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1940 s 
Stanley Kahn, MD 43
Kahn spends time reading, practicing  
the piano, and enjoying his two  
grandchildren.
1950 s 
James Dunlevy, MD 51
Dunlevy is living in the Chippewa  
National Forest on the shores of a huge 
glacier lake in northern Minnesota with  
his wife, Allie (Phelps) Dunlevy, NU 50. 
Their “neighbors” include deer, loons, 
geese, timber wolves, beavers, birds,  
ducks and lots of fish.
John Denman, MD 52
Denman enjoys playing the clarinet in  
a dixie/big band. He also plays golf  
and tennis. He formally retired from  
medicine in 2011.
John Finch, MD 59
Finch’s interests include photography, 
traveling, reading, fishing and family.
1960 s 
David Nelson, MD 63
Nelson is enjoying his retirement in  
Hilton Head SC and is looking forward  
to his 50th reunion. 
Albert Wermuth Jr., MD 67
Wermuth retired from active practice  
in 2009.  
1970 s 
Robin Bernhoft, MD 76
Bernhoft retrained in environmental  
medicine and is enjoying practicing  
“psychological” medicine.
Alice Ackerman, MD 79
Ackerman has become active in social 
media, keeping a children’s health care 
blog at www.carilionclinic.org/blogs/ 
ackerman. She has two young grandsons.
1980 s 
Priscilla Bade, MD 87
Bade is a professor of internal medicine 
at Sanford School of Medicine at the 
University of South Dakota and medical 
director of both the Hospice of the Hills 
and Golden Living Bella Vista in  
Rapid City SD. She coordinates an  
interdisciplinary palliative care course  
for medical and nursing students and was 
a finalist for Medical Director of the Year 
from Golden Living District 4.
1990 s 
Cheryl Whitaker, MD 93
Whitaker was appointed chief medical 
officer of Merge Healthcare. She also was 
appointed by Governor Pat Quinn to the 
board of directors of the Illinois Health 
Information Exchange Authority.
Thomas Allen, MD 97
Allen is an assistant professor of pediatrics  
at the University of Central Florida/
Nemours Children’s Hospital. His pastimes 
include traveling and skiing in Austria.
2000 s
Edward Miner, MD 02
Miner is an interventional cardiologist  
at Utah Heart Clinic in Salt Lake City UT.  
He has five children and enjoys playing 
basketball, skiing and teaching his  
children. Though he no longer lives in  
St. Louis, he is still a Cardinals fan. 
In Memory
Bernard Adler, MD 37
Adler died April 14, 2011. He was 97.
Jerome Madden, DE 42
Madden died April 19, 2011. He is  
survived by five children, five grand- 
children and many friends.
John Martz, MD 42, HS 47
Martz, 95, died April 6, 2012. He served 
as a captain in the U.S. Army Medical 
Corps treating the wounded on the front 
lines in World War II. He retired in 1985 
after 37 years as a pediatrician and as an 
associate professor of clinical pediatrics at 
Washington University School of Medicine.
Virginia Peden, MD 47
Peden died May 28, 2011. She is survived 
by a brother, four children and six  
grandchildren. 
Thomas Zaydon Sr., HS
Zaydon died Jan. 12, 2012. He was  
former chief of plastic surgery at Miami 
Heart Institute, St. Francis, Mount Sinai and 
Mercy Hospital and received numerous 
civic, religious and professional awards.  
He is survived by eight children, seven 
grandchildren, numerous nieces and 
nephews, and many other close family 
members, friends and colleagues. 
Noah Susman, LA 48, MD 52, HS 55
Susman, who died March 1, 2012, was 
professor emeritus of clinical radiology at 
Washington University School of Medicine 
and a former chief of radiology at Jewish 
Hospital of St. Louis. He had been presi-
dent of the Vaad Hoeir of St. Louis, the 
founding president of Block Yeshiva  
High School, a founding member of  
Young Israel Synagogue of St. Louis, and 
a former board member of the Jewish 
Federation of St. Louis. Susman is sur-
vived by his wife, four children, and many 
beloved grandchildren.
William Sawyer, MD 54
Sawyer, 82, died March 20, 2012.  
He served nine years in the U.S. Army  
followed by years of research and  
teaching at Johns Hopkins University 
School of Medicine, Mahidol University in 
Bangkok, Thailand, and Indiana University 
School of Medicine in Indianapolis. He was 
dean of the medical school at Wright State 
University in Dayton OH. He was president, 
until his retirement in 1997, of the China 
Medical Board of New York, a foundation 
that supports research and education in 
medicine, nursing and public health in 
East and Southeast Asia. He was only the 
second American to be awarded the China 
Health Medal for his work in China. This 
was presented in a ceremony in the  
Great Hall of the People in Beijing. Sawyer 
is survived by his wife, two children and 
six grandchildren. 
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If you wish to make a tribute gift in honor 
of any of the above alumni or faculty, 
please contact: Pamela Buell, Washington 
University Medical Alumni and Development, 
Campus Box 1247, 7425 Forsyth Blvd., Suite 2100, 
St. Louis MO 63105-2161, (314) 935-9691.
Lois Gasteyer, NU 55
Gasteyer died Feb. 16, 2012, at age 77.  
She was married to Theodore Hall 
Gasteyer II, MD 57, for 54 years.  
She was active in multiple community 
organizations, including school PTAs and 
the Christ Hospital Women’s Auxiliary.  
She served on the Oak Lawn Library Board 
and was instrumental in the establish-
ment of the Oak Lawn Library Educational 
Foundation. She is survived by her hus-
band, two children and four grandchildren. 
George Koehler, MD 58
Koehler died Jan. 24, 2012, at age 80. He 
specialized in internal medicine and was 
on the staff of St. Luke’s Hospital. He loved 
playing golf and embraced the study of 
the German language with a passion. He 
is survived by his wife, two siblings, two 
children and two grandchildren.  
Faculty 
Michael J. Welch, PhD
Welch, a pioneering radiochemist, died  
May 6, 2012. He was 72. He joined the 
Washington University faculty in 1967, and 
was professor of radiology, of chemistry, 
of biomedical engineering and of devel-
opmental biology. He was the founding 
leader of the Oncologic Imaging Research 
Program at the Alvin J. Siteman Cancer 
Center at Barnes-Jewish Hospital and 
Washington University School of Medicine 
and a member of the cancer center’s 
senior leadership. He was elected to the 
Institute of Medicine and received many  
of his field’s highest honors, including  
the Benedict Cassen Award from the 
Society of Nuclear Medicine. In 2008, the 
society named its award for outstanding  
contributions to radiopharmaceutical 
research after Welch. 
 Emeritus • 1953 • 1958 • 1963  
• 1968 • 1973 • 1978  • 1983  
• 1988 • 1993  • 1998 • 2003
Mark your calendar! 
Make plans to return for the fun and  
excitement of Reunion! Catch up with  
classmates and learn what’s happening  




School updates and tours
Class dinners and photos






Questions? Want to join your Reunion Committee?
medicalalumni@wustl.edu  
314.935.9682 or 877.816.2586
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Benefits can include:
n Retaining control of assets during your lifetime  
to provide for family and loved ones
n Reducing estate taxes
n Supporting scholarships, professorships, research,  
and programs that are important to you
To learn how you can make a planned gift,  
contact the Office of Planned Giving:
(800) 835-3503 or (314) 935-5373
plannedgiving.wustl.edu
Leading together, the Washington University 
community defines the forefront of medical innovation 
— advancing human health, preparing tomorrow’s 
leaders, and enriching the quality of life. A simple yet 
significant way to support these efforts is by making  
a planned gift through your will, trust, life insurance,  
IRA, or qualified retirement plan. 
Together, we can change lives!
For information on supporting the School of Medicine 
through an outright gift, contact:
Pamela Buell, Associate Vice Chancellor for  
Medical Alumni and Development 
(314) 935-9698    email: meddev@wustl.edu 
  Consult with your legal or tax advisor before making a charitable gift.
Poster session in the Farrell Learning and Teaching Center.
 Together
advancing health   
transforming lives
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Transformation
Pipette tip packaging found new 
meaning as sculpture created 
by Material Monster, a student 
group focused on materials reuse 
and education. Caitlin E. Lee, an 
undergraduate fine arts major 
and founder of the group, and 
Susan Q. Shen, a graduate student 
in neuropathology, collaborated 
with artist Catherine A. Leberg 
and other Washington University 
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How the Campaign for Washington University  
will advance human health
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